Reshaping the HIV treatment and prevention landscape
Zejula: maximizing patient benefit through
multiple development opportunities
gsk
Breast (ctDNA+) - ZEST
-
Leverage ctDNA to treat high risk patients after curative therapy
Estimated patient population of ~20k*
NSCLC 1L - ZEAL
-
-
PD1 + PARPi synergy
Differentiation: blood-brain barrier penetration
-
Estimated patient population of ~84k*
Pivotal data readout expected 2024
Endometrial 1L - RUBY
-
Potential for PD1 + PARPi synergy
-
Estimated patient population of ~3k*
Pivotal data readout expected 2025
Ovarian 1L - FIRST
-
Potential for PD1 + PARPi synergy
-
Estimated patient population of ~26k*
Pivotal data readout expected 2023
Pivotal data readout expected 2023
Four pivotal studies to expand the potential value of Zejula
Source: GSK internal data;
*
Eligible annual new patient starts by 2031
96View entire presentation